Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharmacopeia identifies another lead compound for GSK

This article was originally published in Scrip

Executive Summary

Pharmacopeiahas identified another lead compound for the treatment of pain through its collaboration withGlaxoSmithKline, which will pay the US-based company a milestone payment worth $500,000 for the compound. Pharmacopeia has worked with GSK's Centre of Excellence for External Drug Delivery since 2006 and has so far identified five leads for advancement for the multinational – most recently a compound with potential for treating respiratory diseases, for which the company received a similar milestone (Scrip online, June 5th 2008). Pharmacopeia stands to earn up to $83 million in milestone payments per project as well as double-digit sales royalties.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts